```html

Zoster‑Induced Vertigo

What is Zoster‑induced vertigo?

Zoster‑induced vertigo is a type of dizziness that occurs when the varicella‑zoster virus (VZV) – the same virus that causes chickenpox and shingles – affects the inner ear or the vestibular part of the cranial nerves. After a primary infection (chickenpox), VZV remains dormant in nerve ganglia. Reactivation, most commonly as shingles (herpes zoster), can involve the ear (Ramsay Hunt syndrome) or the vestibular nerve, leading to a sensation that the room is spinning, imbalance, and nausea. This condition is medically referred to as herpes zoster‑associated vestibular neuritis or zoster‑induced vertigo.

The vertigo is usually acute, lasting from a few days to several weeks, and may be accompanied by the classic shingles rash on the ear, face, or scalp. Early recognition is important because antiviral therapy can reduce nerve damage and speed recovery.

Common Causes

Vertigo can arise from many different disorders. When it is specifically linked to varicella‑zoster virus, the following conditions are most often implicated:

• Ramsay Hunt syndrome (herpes zoster oticus): Reactivation of VZV in the geniculate ganglion affecting the facial nerve and the vestibulocochlear nerve.
• Herpes zoster vestibular neuritis: Direct inflammation of the vestibular branch of cranial nerve VIII without external ear rash.
• Post‑herpetic neuralgia (PHN) involving the ear: Persistent pain that can dysregulate vestibular pathways.
• Labyrinthitis secondary to VZV: Inflammation of the inner ear’s sensory epithelium.
• Acute otitis media with concurrent VZV reactivation: Bacterial infection may coexist, worsening balance problems.
• Central nervous system (CNS) VZV infection: Rarely, VZV can cause meningitis or encephalitis with vertiginous symptoms.
• Immunosuppression‑related VZV reactivation: Patients on chemotherapy, steroids, or HIV are at higher risk.
• Age‑related immune decline (immunosenescence): The elderly have a higher incidence of shingles and related vestibular complications.
• Traumatic or surgical manipulation of the ear: May trigger VZV reactivation in predisposed individuals.
• Concurrent COVID‑19 infection: Emerging evidence suggests that viral co‑infection can exacerbate VZV‑related vestibular dysfunction.

Associated Symptoms

Patients with zoster‑induced vertigo often experience a constellation of additional signs that help differentiate it from other causes of dizziness.

• Rash or vesicles: Erythematous vesicular rash on the external ear, pinna, or behind the ear (most characteristic).
• Hearing loss: Sudden or progressive sensorineural hearing loss on the affected side.
• Tinnitus: Ringing, buzzing, or roaring in the ear.
• Facial weakness or drooping: When the facial nerve is involved (Ramsay Hunt).
• Nausea and vomiting: Due to the brain’s response to abnormal vestibular input.
• Ear fullness or pressure: A sensation of blockage.
• Post‑herpetic neuralgia: Burning or stabbing pain persisting beyond the rash.
• Balance difficulty (ataxia): Unsteady gait, especially in low‑light conditions.
• Photophobia or headache: May indicate central involvement.

When to See a Doctor

Prompt medical attention can prevent permanent balance problems and reduce the risk of complications. Seek care if you notice any of the following:

• Sudden onset of severe vertigo that lasts > 24 hours.
• Appearance of a painful blistering rash on the ear, face, or scalp.
• Hearing loss, ringing, or ear fullness accompanying dizziness.
• Facial weakness, drooping, or difficulty closing the eye on the same side as the vertigo.
• Persistent vomiting or inability to keep fluids down.
• Symptoms that do not improve within 48‑72 hours after starting antiviral medication.
• History of immunosuppression (e.g., chemotherapy, HIV, chronic steroids).

Diagnosis

Diagnosis relies on a combination of clinical examination, targeted tests, and sometimes imaging.

1. Clinical history and physical exam

• Detailed timeline of rash, pain, hearing changes, and vertigo.
• Inspection of the ear and surrounding skin for vesicles.
• Neurological exam focusing on cranial nerves V, VII, and VIII.
• Bedside vestibular tests (e.g., Dix‑Hallpike maneuver, head‑impulse test).

2. Otoscopic examination

Identifies middle‑ear effusion, tympanic membrane perforation, or external ear lesions.

3. Audiometry

Baseline hearing assessment to document any sensorineural loss.

4. Vestibular function testing

• Video‑head impulse test (vHIT): Detects unilateral vestibular hypofunction.
• Electronystagmography (ENG) / Videonystagmography (VNG): Records eye movements during positional changes.
• Caloric testing: Evaluates each ear’s response to temperature‑stimulated fluid.

5. Laboratory studies

• Polymerase chain reaction (PCR) of vesicular fluid or ear swab for VZV DNA (highly specific).
• Serum VZV IgM/IgG to support recent reactivation.

6. Imaging (when indicated)

• MRI with contrast: Rules out central causes (brainstem stroke, encephalitis) and shows enhancement of the facial or vestibular nerve.
• CT scan: Usually reserved for trauma or when MRI is contraindicated.

Treatment Options

Management combines antiviral therapy, anti‑inflammatory medication, vestibular rehabilitation, and symptom‑focused care.

1. Antiviral medication

• Acyclovir 800 mg five times daily or valacyclovir 1 g three times daily for 7‑10 days.
• Initiate within 72 hours of rash onset for maximal benefit (reduces nerve damage by ~30%).

2. Corticosteroids

• Prednisone 60 mg daily, tapered over 5‑10 days, can lessen inflammation of the vestibular nerve.
• Use is controversial in immunocompromised patients; weigh risks and benefits.

3. Pain control

• Gabapentin or pregabalin for neuropathic pain.
• Acetaminophen or NSAIDs for mild to moderate discomfort.

4. Vestibular suppressants (short‑term)

• Meclizine 25‑50 mg every 6 hours or dimenhydrinate.
• Limit use to first 48‑72 hours; prolonged suppression can delay central compensation.

5. Vestibular rehabilitation therapy (VRT)

• Guided exercises (gaze stabilization, balance training) prescribed by a physical therapist.
• Proven to improve functional recovery in 70‑80 % of patients within 3 months (Cochrane Review 2022).

6. Supportive home measures

• Stay hydrated and eat light meals to reduce nausea.
• Sleep with the head slightly elevated.
• Avoid sudden head movements; use railings when standing.
• Limit alcohol and caffeine, which can exacerbate dizziness.

Prevention Tips

Because zoster‑induced vertigo stems from VZV reactivation, preventing shingles is the cornerstone of prevention.

• Shingles vaccine: Recombinant zoster vaccine (Shingrix) recommended for adults ≥50 years and for immunocompromised adults 19 years or older. Two doses, 2‑6 months apart, >90 % efficacy in preventing shingles and its complications.
• Maintain a healthy immune system: Adequate sleep, balanced diet, regular exercise, and stress management.
• Control chronic conditions: Diabetes, hypertension, and HIV increase reactivation risk; keep them well‑managed.
• Prompt treatment of initial shingles: Early antiviral therapy reduces the chance of vestibular involvement.
• Avoid exposure to VZV when immunocompromised: Pregnant women, newborns, and patients on chemotherapy should limit contact with individuals who have active chickenpox or shingles.

Emergency Warning Signs

Key Take‑aways

• Zoster‑induced vertigo results from VZV reactivation affecting the inner ear or vestibular nerve, often heralded by a painful ear rash.
• Early antiviral therapy (within 72 hours) and a short course of steroids dramatically improve outcomes.
• Vaccination with Shingrix is the most effective preventive measure.
• Persistent or worsening symptoms, facial weakness, hearing loss, or signs of stroke warrant immediate medical evaluation.

For personalized guidance, always discuss symptoms and treatment options with your health‑care provider. The information above reflects current recommendations from reputable sources including the Mayo Clinic, CDC, NIH, WHO, and peer‑reviewed studies up to 2024.

```